Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607167 | 0.88 | TP53 (0.64) | TP53LMNAPTGDR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL10036740 | 0.87 | TP53 (0.59) | TP53LMNAPTGDR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6525505 | 0.86 | L3MBTL1 (0.55) | PTGDR2ALDH1A1TSHRCMA1PKM | |
| SCHEMBL5361219 | 0.85 | TP53 (0.72) | TP53LMNAPTGDR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL30327555 | 0.85 | TP53 (0.64) | TP53LMNAPTGDR2 | |
| SCHEMBL14064651 | 0.84 | TP53 (0.65) | TP53LMNAPTGDR2ALDH1A1TSHR | |
| SCHEMBL607145 | 0.83 | TP53 (0.59) | TP53LMNAPTGDR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL11964655 | 0.83 | TP53 (0.59) | TP53LMNAPTGDR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2117377 | 0.82 | TP53 (0.55) | TP53LMNAPTGDR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL607289 | 0.79 | KMT2A (0.46) | PTGDR2ALDH1A1CMA1CHRM5CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139331-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | The Regents of the University of Michigan (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008112553-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-18 | — | — | WO | claimed |
| CN-118055923-A | Benzodiazepine derivatives as positive allosteric modulators of the GABAA γ1 receptor | 豪夫迈·罗氏有限公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-2217576-B1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | UNIV MICHIGAN (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2217576-B1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | UNIV MICHIGAN (US) | 2016-05-11 | — | — | EP | disclosed |
| US-8759340-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759340-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-24 | — | — | US | disclosed |
| US-8673897-B2 | Benzodiazepinone compounds and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673897-B2 | Benzodiazepinone compounds and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673897-B2 | Benzodiazepinone compounds and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080269194-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269194-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269194-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008112553-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112553-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007146167-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269194-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | BAX, BAD, BAK1 | TP53 1367/4885LMNA 2006/4885PTGDR2 253/4885 |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | TP53 3879/4885LMNA 2002/4885PTGDR2 258/4885 |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | TP53 3879/4885LMNA 2002/4885PTGDR2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.